In Belgium, linezolid is indicated for pneumonia and skin and soft tissue infections, but is more broadly used, due to its oral bioavailability and activity against multiresistant organisms. This could increase the risk of adverse drug reactions (ADR), notably hematological disorders (anemia, thrombocytopenia), neuropathy, or lactic acidosis. We analyzed linezolid clinical use in relationship with occurrence of ADR in Belgian hospitals and highlighted risk factors associated with the development of thrombocytopenia. A retrospective analysis of electronic medical records and laboratory tests of adult patients treated with linezolid in four Belgian hospitals in 2016 allowed the collection of ADR for 248 linezolid treatments. Only 19.7% of indications were in-label. ADR included 43 thrombocytopenia, 17 anemia, 4 neuropathies, and 4 increases in lactatemia. In a multi-variate analysis, risk factors of thrombocytopenia were a treatment duration > 10 days, a glomerular filtration rate < 60 mL/min, and a Charlson index ≥ 4. Off-label use of linezolid is frequent in Belgium, and ADR more frequent than reported in the summary of product characteristics, but not statistically associated with any indication. This high prevalence of ADR could be related to a high proportion of patients presenting risk factors in our population, highlighting the importance of detecting them prospectively.
31 March 2023 in Kidney Research and Clinical Practice
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is particularly life threatening in patients who are immunocompromised, including those with advanced chronic kidney disease (CKD) [1,2]. Despite the implementation of a third dose of a messenger RNA (mRNA) vaccine, the efficacy of SARS-CoV-2 vaccination on humoral and cellular immunities is reduced in the population with CKD, resulting in an increased incidence of severe infection and mortality, including in fully vaccinated patients [3]. In this context, several antiviral therapies or monoclonal antibodies are being investigated for treatment of COVID-19. These drugs prevent viral replication through various mechanisms, including neutralization, blocking SARS-CoV-2 entry, and inhibiting RNA polymerase or proteases activity [4,5]. However, patients with CKD are frequently excluded from clinical trials evaluating new drugs. Although sotrovimab and casirivimab/imdevimab have been shown to confer satisfactory protection against the COVID-19 Delta variant, they have limited neutralizing activity against the Omicron variant [4]. Remdesivir, nirmatrelvir/ritonavir, bebtelovimab, and molnupiravir seem to be effective against the Omicron variant [5]. U.S. Food and Drug Administration product labels do not recom
27 November 2023 in Open Forum Infectious Diseases
Patients received first meropenem 2g q8h. At steady state ( > 3 doses), 4 blood samples were collected over 8h. The penultimate day of the treatment, patients were switched to the OPAT-compatible dosage regimen (2g q6h over 12h) and, at steady state, a total of 8 blood samples were collected during the first and third dosing intervals. Unbound meropenem concentrations were determined in ultrafiltrated plasma by a validated LC-MS/MS procedure. Time above MICs ≤ 8 mg/L (EUCAST susceptibility breakpoint) were estimated for both schemes based on PK profiles. Twenty-two patients were included. The mean pharmacokinetic profile for each scheme is shown in the Figure 1. The Table 1 shows that plasma concentrations remained > 4 mg/L during 100% time with the conventional scheme and > 2 mg/L with the OPAT-compatible scheme but still at least ∼80% time > 8 mg/L with both therapeutic schemes. Periods of inadequate coverage are spread at the end of each dose with the conventional dosing regimen but essentially concentrated overnight with the new scheme. PK/PD models recommend for meropenem therapeutic schemes with plasma concentrations > MIC during 30-40% of the time in non-critically ill patients. This target is easily achieved with the proposed OPAT-compatible dosing regimen, including during night, and could therefore be safely used in a context of limited nurse resources. All Authors: No reported disclosures
1 July 2026 in Antimicrobial Agents and Chemotherapy
Meropenem is a valuable option for outpatient parenteral antimicrobial therapy (OPAT) due to its broad-spectrum activity, including multidrug-resistant Gram-negative bacteria, particularly when no oral alternatives exist. However, its conventional thrice-daily dosing poses logistical challenges for home administration, as the third dose typically falls during nighttime. This prospective pharmacokinetic study evaluated the adequacy of a novel daytime-only meropenem regimen adapted for OPAT in non-critically ill hospitalized patients. Twenty-two patients receiving meropenem 2 g every 8 h were switched, once clinically stable, to a thrice-daily, 6-hourly regimen compatible with daytime administration only. Meropenem was infused over 20 min. At steady state, unbound meropenem concentrations were measured for both regimens. These data informed a population pharmacokinetic model and Monte Carlo simulations to compare the probability of achieving predefined PK/PD targets. Both the conventional and OPAT-adapted regimens achieved a probability of target attainment (PTA) >90% for 40% f T >MIC at MIC ≤4 mg/L, exceeding the EUCAST/IDSA susceptibility breakpoint of 2 mg/L. Extending the infusion duration to 3 or 5 h with the OPAT-adapted schedule restored PTA >90% for MIC ≤8 mg/L. However, trough concentrations after the evening dose were lower with the OPAT-adapted regimen than with the standard regimen (1–2 vs 3–5 mg/L, depending on infusion duration). This may increase the risk of resistance selection despite the post-antibiotic effect of meropenem. With this caveat, OPAT regimens, with infusion duration adapted to MIC, may enable practical daytime-only meropenem administration, avoiding the need for overnight nursing visits.